Health Care & Life Sciences » Pharmaceuticals | Shanghai Kaibao Pharmaceutical Co. Ltd.

Shanghai Kaibao Pharmaceutical Co. Ltd. | Income Statement

Fiscal year is January-December. All values CNY Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,310
1,466
1,381
1,480
1,553
1,486
Cost of Goods Sold (COGS) incl. D&A
211
237
261
290
300
274
Gross Income
1,099
1,229
1,120
1,190
1,253
1,212
SG&A Expense
770
843
822
866
950
922
EBIT
329
386
298
325
304
290
Unusual Expense
-
-
-
1
2
53
Non Operating Income/Expense
1
1
3
13
3
14
Interest Expense
-
-
-
-
2
-
Pretax Income
377
415
335
334
332
278
Income Tax
58
65
53
51
55
48
Equity in Affiliates
-
-
-
-
5
3
Consolidated Net Income
319
349
282
283
272
227
Net Income
319
349
282
283
272
227
Net Income After Extraordinaries
319
349
282
283
272
227
Net Income Available to Common
319
349
282
283
272
227
EPS (Basic)
0.30
0.33
0.26
0.26
0.25
0.21
Basic Shares Outstanding
1,067
1,068
1,083
1,082
1,071
1,071
EPS (Diluted)
0.30
0.33
0.26
0.26
0.25
0.21
Diluted Shares Outstanding
1,067
1,068
1,083
1,082
1,071
1,071
EBITDA
359
424
349
373
353
338
Other Operating Expense
-
-
-
2
1
-
Non-Operating Interest Income
25
24
30
21
24
28

About Shanghai Kaibao Pharmaceutical Co.

View Profile
Address
No. 88, Chengpu Road
Shanghai Shanghai 201401
China
Employees -
Website http://www.xykb.com
Updated 07/08/2019
Shanghai Kaibao Pharmaceutical Co., Ltd. engages in the research, development, manufacture and sale of modern Chinese medicine. Its medicines are in the form of injection, tablets, hard capsules, granules, mixture, syrup, oral liquid, and Chinese medicine extraction; such as Tanreqing injection, doxofylline capsule, Captopril sustained-release tablets, and Hydrochloride pioglitazone tablets. The company was founded on April 12, 2000 and is headquartered in Shanghai, China.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.